Stockscreener 앱 받기
4.72
0.21%
-0.01
시간 외 거래:
4.65
-0.07
-1.48%
전일 마감가:
$4.73
열려 있는:
$4.67
하루 거래량:
142.18K
Relative Volume:
0.75
시가총액:
$178.67M
수익:
$147.12M
순이익/손실:
$-33.88M
주가수익비율:
-9.8231
EPS:
-0.4805
순현금흐름:
$-13.62M
1주 성능:
-5.79%
1개월 성능:
+2.39%
6개월 성능:
-33.33%
1년 성능:
-36.39%
1일 변동 폭
$4.4735
$4.75
1주일 범위
$4.4735
$5.0022
52주 변동 폭
$3.625
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
명칭
Lifecore Biomedical Inc
전화
(952) 368-4300
주소
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
4.72 | 180.56M | 147.12M | -33.88M | -13.62M | -0.4805 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2025-09-04 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2025-05-21 | 개시 | William Blair | Outperform |
| 2024-09-05 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
모두보기
Lifecore Biomedical Inc 주식(LFCR)의 최신 뉴스
Avoiding Lag: Real-Time Signals in (LFCR) Movement - Stock Traders Daily
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript - AOL.com
Judge approves $3.75 million Lifecore investor settlement - minnlawyer.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - marketscreener.com
Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Discipline and Rules-Based Execution in LFCR Response - news.stocktradersdaily.com
Earnings call transcript: Lifecore Biomedical tops revenue view in Q2 2026 - Investing.com Canada
Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Transcript : Lifecore Biomedical, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026 - marketscreener.com
Lifecore Biomedical, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Lifecore Biomedical Q2 Earnings Call Highlights - marketbeat.com
Lifecore Biomedical, Inc. (LFCR) Q2 FY2026 earnings call transcript - Yahoo Finance
LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmed - TradingView
Lifecore Biomedical Backs 2026 Adj EBITDA of $20.5M-$25M >LFCR - Moomoo
Lifecore Biomedical Q2 revenue falls to $34.2 million as loss widens - Quiver Quantitative
Lifecore Biomedical 2026: Revenue $34.17M, EPS ($0.19) — 10-Q Summary - TradingView
Lifecore Biomedical: Q2 Earnings Snapshot - marketscreener.com
Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed - Stock Titan
Press Release: Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - moomoo.com
LFCR: Q2 2026 delivered strong revenue, margin expansion, and robust pipeline growth - TradingView
Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million - Bitget
Lifecore Biomedical Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Zacks Research Upgrades Lifecore Biomedical (NASDAQ:LFCR) to Hold - marketbeat.com
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026 - GlobeNewswire
Lifecore Sets Aug. 5 Webcast for Second-Quarter Results - Stock Titan
Lifecore Biomedical (LFCR) Tests Resistance After a Modest UptickBull Flag - dars.gov.et
Lifecore Biomedical signs three new customer de... - Pluang
Lifecore Biomedical Signs Three New Customer Agreements - The Manila Times
Lifecore Biomedical Announces Three New Customer Agreements Spanning Late-Stage Regenerative Medicine and Early-Stage Development Programs - Quiver Quantitative
Regenerative Medicine and Device Programs Expand Lifecore’s Pipeline - Stock Titan
Lifecore Biomedical Inc (LFCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lifecore Biomedical Inc (LFCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LFCR|Lifecore Biomedical Inc|Price:4.330|Chg%:-0.100 - TradingKey
Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lifecore Biomedical (LFCR) Slips 2.26% as Stock Tests Key Support Near $4.11Defined Outcome ETF - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical - The National Law Review
Lifecore Biomedical, Inc. Revenue Breakdown – NASDAQ:LFCR - TradingView
Lifecore Biomedical (LFCR) Pulls Back: Testing Key Support After 2.26% DeclineNegative Gamma - dars.gov.et
Lifecore Biomedical Inc. (LFCR) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Operational ChallengesBook Value Growth - dars.gov.et
LFCR|Lifecore Biomedical Inc|Price:4.340|Chg%:+0.010 - TradingKey
Lifecore Biomedical (LFCR) Q1 2026 earnings summary - Quartr
Lifecore Biomedical (LFCR) Proxy filing Summary - Quartr
LFCR Deadline: LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit - GuruFocus
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
What Triggered Lifecore Biomedical's Recent Stock Plunge - Kavout | AI
New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years - Stock Titan
Lifecore Biomedical Inc (LFCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
5.15%
자본화:
|
볼륨(24시간):